Law360, New York (January 22, 2008, 12:00 AM ET) -- While the European Commission appears to have taken a cue from the U.S. Federal Trade Commission in cracking down on potential antitrust issues and patent abuse in the pharmaceutical industry, the EC's inquiry began in a unique fashion: with unannounced dawn raids typically reserved for cartels. The approach of the EC is likely to differ from that of the U.S. in other ways, too, attorneys say.
The EC has said that its sectorwide investigation will examine whether reverse deals between makers of brand-name drugs and their...
EU Pharma Probe Expected To Veer From FTC Course
To view the full article, take a free trial now.
